Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide with Radiotherapy in NSCLC with Brain Metastases
NCT00266812Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of temozolomide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free Survival at 6 months. Started Mar 2005; status: terminated.
02
Drugs
temozolomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00266812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266812.